| Code | CSB-RA884484MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Solnerstotug, targeting VSIR (V-Set Immunoregulatory Receptor), also known as VISTA or PD-1H. VSIR functions as an immune checkpoint protein predominantly expressed on myeloid cells and T lymphocytes, where it delivers inhibitory signals that suppress T cell activation and proliferation. This immunoregulatory molecule plays a critical role in maintaining immune homeostasis and self-tolerance. VSIR has emerged as a significant target in immuno-oncology research, as its expression in the tumor microenvironment contributes to immune evasion mechanisms in various cancers, including melanoma, ovarian cancer, and hematological malignancies.
Solnerstotug represents a clinical-stage therapeutic antibody designed to block VSIR-mediated immunosuppression, thereby enhancing anti-tumor immune responses. This biosimilar antibody provides researchers with a valuable tool for investigating VSIR biology, exploring immune checkpoint mechanisms, and developing novel immunotherapeutic strategies. It supports studies examining T cell regulation, myeloid cell function, and tumor immunity, making it particularly relevant for cancer immunology and autoimmune disease research.
There are currently no reviews for this product.